Deutsche Bank announced on Tuesday that it had lowered its target price for Eurofins Scientific from €56 to €54, while reiterating its 'sell' recommendation on the stock.

Having examined the accounts of the group's 280 European subsidiaries in order to gain a better understanding of its business model, the analyst deduced that the bio-analysis giant would need to significantly improve its performance across all its business lines in order to meet its 2027 targets.

However, he points out, such a phenomenon has never occurred historically, with the sole exception of the Covid crisis, which gave the diagnostics industry a boost.

'In view of these factors, we remain cautious as to the reality of such a major improvement', he stresses.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.